948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: Analysis of number needed to treat and number needed to harm
    Journal Article

    Sugarman, R.; Betts, K. A.; Nie, X.; Hartman, J.; Nguyen, H.
    Clinical Therapeutics (2023)

    Fulltext@MSK | Save
  • Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
    Journal Article

    Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Galvez, C. C.; Smit, E. F.; Garassino, M.; Veillon, R.; Baz, D. V.; Pradera, J. F.; more...
    Cell Reports Medicine (2023)

    Fulltext@MSK | Save
  • Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
    Review

    Santinelli, E.; Pascale, M. R.; Xie, Z.; Badar, T.; Stahl, M. F.; Bewersdorf, J. P.; Gurnari, C.; Zeidan, A. M.
    Blood Reviews (2023)

    Fulltext@MSK | Save
  • Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events
    Review

    Gu, S. L.; Nath, S.; Markova, A.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer
    Journal Article

    Van Cutsem, E.; Yaeger, R.; Delord, J. P.; Tabernero, J.; Siu, L. L.; Ducreux, M.; Siena, S.; Elez, E.; Kasper, S.; Zander, T.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: A prospective multicenter observational cohort study
    Journal Article

    Zhang, Y.; Shen, G.; Xu, R.; Huang, G.; Huang, Z.; Duan, H.; Yang, S.; Zheng, Q.; Yang, L.; Liu, R.; more...
    Journal of Thoracic Disease (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 SELENE study: Ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
    Journal Article

    Nastoupil, L. J.; Hess, G.; Pavlovsky, M. A.; Danielewicz, I.; Freeman, J.; García-Sancho, A. M.; Glazunova, V.; Grigg, A.; Hou, J. Z.; Janssens, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
    Journal Article

    Kummar, S.; Shen, L.; Hong, D. S.; McDermott, R.; Keedy, V. L.; Casanova, M.; Demetri, G. D.; Dowlati, A.; Melcón, S. G.; Lassen, U. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save